Thyroid hormone, thyroid hormone receptors, and cancer: a clinical perspective
The DOI matches its Crossref record; 79 of the 79 references it cites were found in a registry or an index.
Abstract
Thyroid hormones (THs) may play a role in diseases other than hyper- and hypothyroidism. Several lines of evidence suggest tumor-promoting effects of TH and TH receptors. They are possibly mediated by phosphatidylinositol-3-kinase and MAPK and involve among others stimulation of angiogenesis via αvβ3. Thus, an increased risk for colon, lung, prostate, and breast cancer with lower TSH has been demonstrated in epidemiological studies, even suggesting a TH dose effect on cancer occurrence. Furthermore, higher TH levels were associated with an advanced clinical stage of breast and prostate cancer. In rodent models, TH stimulated growth and metastasis of tumor transplants, whereas hypothyroidism had opposite effects. In clinical studies of glioblastoma and head and neck cancer, hypothyroid patients showed longer survival than euthyroid patients. Also, patients with renal cell cancer that were treated with the tyrosine kinase inhibitor sunitinib and developed hypothyroidism in due course showed significantly longer survival than patients that remained euthyroid. Development of hypothyroidism was an independent predictor for survival in two studies. Yet, it is still possible that hypothyroidism is only a surrogate marker for treatment efficacy and does not positively influence treatment outcome by itself. Future cancer treatment studies, especially with substances that can induce hypothyroidism, should therefore be designed in a way that allows for an analysis of thyroid function status and its contribution on treatment outcome.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Thyroid dysfunction, mostly hypothyroidism, is an adverse effect of checkpoint inhibitor treatment for cancer, and has been associated with longer survival in these studies (36,37).”
From Evidence-Based Use of Levothyroxine/Liothyronine Combinations in Treating Hypothyroidism: A Consensus Document (2021) · cites this paper as [37]
In the citing paper
“Thyroid dysfunction, mostly hypothyroidism, is an adverse effect of checkpoint inhibitor treatment for cancer, and has been associated with longer survival in these studies [36, 37].”
From Evidence-Based Use of Levothyroxine/Liothyronine Combinations in Treating Hypothyroidism: A Consensus Document (2021) · cites this paper as [37]
Citations
Cites
Physiological and Molecular Basis of Thyroid Hormone Action
Yen, P. M. (2001) · Physiological Reviews · doi:10.1152/physrev.2001.81.3.1097 · Cited by 2,011 · cited 1×
“Two different genes, THRA on chromosome 17 and THRB on chromosome 3, encode TRa and TRb respectively (Yen 2001).”
BackgroundDefining the role of hypoxia-inducible factor 1 in cancer biology and therapeutics
Semenza, G. L. (2010) · Oncogene · doi:10.1038/onc.2009.441 · Cited by 1,712
Interaction of oestrogen receptor with the regulatory subunit of phosphatidylinositol-3-OH kinase
Simoncini, T., Hafezi-Moghadam, A., Brazil, D. P., Ley, K., Chin, W. W., & Liao, J. K. (2000) · Nature · doi:10.1038/35035131 · Cited by 1,436 · cited 1×
“…that TH and TRb could also act through a different mechanism: the ligand-bound TRb could activate the phosphatidylinositol-3-kinase (PI3K) pathway via phosphorylation of Akt/PKB within minutes, which subsequently affected gene expression (Simoncini et al. 2000, Lei et al. 2004, Cao et al. 2005).”
BackgroundMolecular Aspects of Thyroid Hormone Actions
Cheng, S.-Y., Leonard, J. L., & Davis, P. J. (2010) · Endocrine Reviews · doi:10.1210/er.2009-0007 · Cited by 1,384 · cited 1×
“In addition, truncated TR isoforms exist that lack amino terminal domains and DNA binding (Cheng et al. 2010).”
BackgroundPTEN and the PI3-Kinase Pathway in Cancer
Chalhoub, N., & Baker, S. J. (2009) · Annual Review of Pathology: Mechanisms of Disease · doi:10.1146/annurev.pathol.4.110807.092311 · Cited by 1,245 · cited 1×
“And the oncogenic PI3K pathway, activated by TH via TRa/b and the S1 site of avb3, facilitates cell growth and survival and inhibits apoptosis (Chalhoub & Baker 2009).”
BackgroundBergh, J. J., Lin, H.-Y., Lansing, L., Mohamed, S. N., Davis, F. B., Mousa, S., & Davis, P. J. (2005) · Endocrinology · doi:10.1210/en.2005-0102 · Cited by 497
Rapid nongenomic actions of thyroid hormone
Hiroi, Y., Kim, H.-H., Ying, H., Furuya, F., Huang, Z., Simoncini, T., Noma, K., Ueki, K., Nguyen, N.-H., Scanlan, T. S., et al. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0601600103 · Cited by 380 · cited 1×
“Cao et al. (2009) could demonstrate PI3K activation in TRa overexpressing neuronal cells and Hiroi et al. (2006) found TRa1 association with p85a followed by phosphorylation of Akt/PKB, a downstream target of PI3K, and activation of endothelial nitric oxide synthase. avb3 as TR Bergh et al. (2005)…”
BackgroundA Mutation in the Thyroid Hormone Receptor Alpha Gene
Bochukova, E., Schoenmakers, N., Agostini, M., Schoenmakers, E., Rajanayagam, O., Keogh, J. M., Henning, E., Reinemund, J., Gevers, E., Sarri, M., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1110296 · Cited by 379 · cited 1×
“The clinical differences between patients with resistance to TH (RTH) due to TRb and TRa mutations further demonstrate that distinct physiological roles for the TR isoforms exist (Refetoff & Dumitrescu 2007, Bochukova et al. 2012, Ferrara et al. 2012, van Mullem et al. 2012).”
BackgroundFactors Related to Inflammation of the Ovarian Epithelium and Risk of Ovarian Cancer
Ness, R. B., Grisso, J. A., Cottreau, C., Klapper, J., Vergona, R., Wheeler, J. E., Morgan, M., & Schlesselman, J. J. (2000) · Epidemiology · doi:10.1097/00001648-200003000-00006 · Cited by 363 · cited 2×
“history of ovarian cancer) (Ness et al. 2000).”
BackgroundInfluentialA Mutation in the Thyroid Hormone Receptor Alpha Gene
Bochukova, E. G., Schoenmakers, N. A., Agostini, M., Schoenmakers, E., Rajanayagam, O., Keogh, J. M., Henning, E., Reinemund, J., Gevers, E. F., Sarri, M., et al. (2012) · UCL Discovery (University College London) · Cited by 327
Research works printed but not linked: 1
- Speranza G Rubinstein L Ivy SP Harris PJ 2011 Correlation between adverse event reports of hypothyroidism and clinical response in patients treated with vascular endothelial growth factor receptor inhibitors (VEGFR-I). Journal of Clinical Oncology29(Supplement: ASCO Meeting Abstracts Part 1) abstract 2602 · doi:10.1200/jco.2011.29.15_suppl.2602
Cited by
de Filette, J., Andreescu, C., Cools, F., Bravenboer, B., & Velkeniers, B. (2019) · Hormone and Metabolic Research · doi:10.1055/a-0843-3366 · Cited by 381
“[134], observations in mouse models suggest that hypothyroidism induced by propylthiouracil suppresses tumor growth, whereas T4 administration had the opposite effect [135, 136].”
BackgroundBelfiore, L., Saunders, D. N., Ranson, M., Thurecht, K. J., Storm, G., & Vine, K. L. (2018) · Journal of Controlled Release · doi:10.1016/j.jconrel.2018.02.040 · Cited by 294
Thyroid Hormones and Cancer: A Comprehensive Review of Preclinical and Clinical Studies
Krashin, E., Piekiełko-Witkowska, A., Ellis, M., & Ashur-Fabian, O. (2019) · Frontiers in Endocrinology · doi:10.3389/fendo.2019.00059 · Cited by 217
“A great deal of research has been conducted in recent decades to determine how thyroid hormones exert their growth-promoting effect (7).”
BackgroundJonklaas, J., Bianco, A. C., Cappola, A. R., Celi, F. S., Fliers, E., Heuer, H., McAninch, E. A., Moeller, L. C., Nygaard, B., Sawka, A. M., et al. (2021) · Thyroid® · doi:10.1089/thy.2020.0720 · Cited by 172
“Thyroid dysfunction, mostly hypothyroidism, is an adverse effect of checkpoint inhibitor treatment for cancer, and has been associated with longer survival in these studies (36,37).”
Self-citationHoffman, K., Lorenzo, A., Butt, C. M., Hammel, S. C., Henderson, B. B., Roman, S. A., Scheri, R. P., Stapleton, H. M., & Sosa, J. A. (2017) · Environment International · doi:10.1016/j.envint.2017.06.021 · Cited by 167
“…including thyroid, suggesting that chemicals that disrupt 65 thyroid hormone homeostasis in a significant way could contribute to cancer risk or severity (e.g. 66 Lin et al. 2016; Hellevik et al. 2009; D'Avanzo et al. 2005; Brinton et al. 2007; Søgaard et al 67 2016; Moeller and Führer 2013).”
BackgroundLiu, Y., Yeh, C., & Lin, K. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20204986 · Cited by 171
Thyroid Function and Cancer Risk: The Rotterdam Study
Khan, S. R., Chaker, L., Ruiter, R., Aerts, J. G. J. V., Hofman, A., Dehghan, A., Franco, O. H., Stricker, B. H. C., & Peeters, R. P. (2016) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2016-2104 · Cited by 144
Hyperthyroidism, Hypothyroidism, and Cause-Specific Mortality in a Large Cohort of Women
Journy, N. M. Y., Bernier, M.-O., Doody, M. M., Alexander, B. H., Linet, M. S., & Kitahara, C. M. (2017) · Thyroid · doi:10.1089/thy.2017.0063 · Cited by 119
Thyroid dysfunction and cancer incidence: a systematic review and meta-analysis
Tran, T.-V.-T., Kitahara, C. M., de Vathaire, F., Boutron-Ruault, M.-C., & Journy, N. (2020) · Endocrine-Related Cancer · doi:10.1530/erc-19-0417 · Cited by 98
“2011), causing phosphorylation by MAPK pathways, binding in the integrin αvβ3 (Moeller & Führer 2013, Hercbergs et al.”
BackgroundThyroid Hormone, Cancer, and Apoptosis
Lin, H., Chin, Y., Yang, Y. S. H., Lai, H., Whang‐Peng, J., Liu, L. F., Tang, H., & Davis, P. J. (2016) · Comprehensive Physiology · doi:10.1002/cphy.c150035 · Cited by 96
Huang, H., Rusiecki, J. A., Zhao, N., Chen, Y., Ma, S., Yu, H., Ward, M. H., Udelsman, R., & Zhang, Y. (2017) · Cancer Epidemiology Biomarkers & Prevention · doi:10.1158/1055-9965.epi-16-0845 · Cited by 95
“Thyroid hormones have also been suggested to have a tumor-promoting effect on several cancers, including pancreatic, breast, ovarian, and prostate cancers (13).”
BackgroundHercbergs, A., Johnson, R. E., Ashur-Fabian, O., Garfield, D. H., & Davis, P. J. (2015) · The Oncologist · doi:10.1634/theoncologist.2014-0308 · Cited by 88
Fitzgerald, S. P., Bean, N. G., Falhammar, H., & Tuke, J. (2020) · Thyroid® · doi:10.1089/thy.2019.0535 · Cited by 86
“Other indicators supporting a causative relationship between thyroid function and at least some of the parameters we examined include the relationships being seen in otherwise healthy individuals (91–99), the prospective nature of many of our included studies, our sensitivity study, the observed similarity of the rela…”
ResultHepburn, A. C., Steele, R. E., Veeratterapillay, R., Wilson, L., Kounatidou, E. E., Barnard, A., Berry, P., Cassidy, J., Moad, M., El‐Sherif, A., et al. (2019) · Oncogene · doi:10.1038/s41388-019-0712-y · Cited by 98
Jonklaas, J., Bianco, A. C., Cappola, A. R., Celi, F. S., Fliers, E., Heuer, H., McAninch, E. A., Moeller, L. C., Nygaard, B., Sawka, A. M., et al. (2021) · European Thyroid Journal · doi:10.1159/000512970 · Cited by 78
Self-citationFrau, C., Loi, R., Petrelli, A., Perra, A., Menegon, S., Kowalik, M. A., Pinna, S., Leoni, V. P., Fornari, F., Gramantieri, L., et al. (2014) · Hepatology · doi:10.1002/hep.27399 · Cited by 72
Keyl, J., Keyl, P., Montavon, G., Hosch, R., Brehmer, A., Mochmann, L. H., Jurmeister, P. S., Dernbach, G., Kim, M., Koitka, S., et al. (2025) · Nature Cancer · doi:10.1038/s43018-024-00891-1 · Cited by 99
“These results are consistent with previously reported findings 26–29 .”
Thyroid Dysfunction, Thyroid Hormone Replacement and Colorectal Cancer Risk
Boursi, B., Haynes, K., Mamtani, R., & Yang, Y. (2015) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djv084 · Cited by 77
“Thyroid hormones exert their biological effect primarily through their nuclear receptors, TRα1 and TRβ1, and a cell surface receptor, integrin αVβ3 (30).”
BackgroundMiro, C., Giovanni, A. D., Murolo, M., Cicatiello, A. G., Nappi, A., Sagliocchi, S., Cicco, E. D., Morra, F., Celetti, A., Pacifico, F., et al. (2022) · Cancer Letters · doi:10.1016/j.canlet.2022.215581 · Cited by 71
Role of the Thyroid System in Myelination and Neural Connectivity
Calzà, L., Fernández, M., & Giardino, L. (2015) · Comprehensive physiology · doi:10.1002/cphy.c140035 · Cited by 73
Ryödi, E., Metso, S., Jaatinen, P., Huhtala, H., Saaristo, R., Välimäki, M. J., & Auvinen, A. P. (2015) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2015-1874 · Cited by 57
“Thyroid hormones enhance metabolism and may play a role in tumor progression (8).”
BackgroundKim, E. Y., Chang, Y., Lee, K. H., Yun, J., Park, Y. L., Park, C. H., Ahn, J., Shin, H. C., & Ryu, S. (2019) · International Journal of Cancer · doi:10.1002/ijc.32283 · Cited by 54
“Thyroid hormone receptor binding can activate the oncogenic phosphoinositide 3-kinase (PI3K) pathway of breast cancer, independent of DNA binding.(33) Specific alterations in thyroid hormone receptors (TRs) have been found in breast cancer, and many studies observed associations between the expression of TRs and the r…”
BackgroundThyroid Hormone Controls Breast Cancer Cell Movement via Integrin αV/β3/SRC/FAK/PI3-Kinases
Flamini, M. I., Uzair, I., Pennacchio, G. E., Neira, F. J., Mondaca, J. M., Cuello-Carrión, F. D., Jahn, G. A., Simoncini, T., & Sanchez, A. M. (2017) · Hormones and Cancer · doi:10.1007/s12672-016-0280-3 · Cited by 47
“Hypothyroidism has been repeatedly associated with a reduced breast cancer risk, a more indolent invasive disease [17, 27, 28], and lower occurrence of metastasis and cell invasion [25].”
BackgroundJohannsson, G., Touraine, P. A., Feldt‐Rasmussen, U., Pico, A. M., Vila, G., Mattsson, A. F., Carlsson, M. O., Korbonits, M., van Beek, A. P., Wajnrajch, M. P., et al. (2022) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgac199 · Cited by 53
Thyroid hormone receptor α in breast cancer: prognostic and therapeutic implications
Jerzak, K. J., Cockburn, J., Pond, G. R., Pritchard, K. I., Narod, S. A., Dhesy‐Thind, S., & Bane, A. L. (2014) · Breast Cancer Research and Treatment · doi:10.1007/s10549-014-3235-9 · Cited by 46
Tosovic, A., Bondeson, A.-G., Bondeson, L., Ericsson, U.-B., & Manjer, J. (2014) · BMC Cancer · doi:10.1186/1471-2407-14-536 · Cited by 40
“In addition, point mutations in breast cancer, that may affect tumour behaviour, have also been detected in the genes encoding TRα and TRβ [32].”
BackgroundLu, L., Wan, B., Li, L., & Sun, M. (2022) · Frontiers in Endocrinology · doi:10.3389/fendo.2022.987401 · Cited by 45
Weng, C., Chen, Y.-H., Lin, C., Luo, X., & Lin, T. (2018) · BMJ Open · doi:10.1136/bmjopen-2017-020194 · Cited by 40
Low thyroid hormone levels improve survival in murine model for ocular melanoma
Fabian, I. D., Rosner, M., Fabian, I., Vishnevskia-Dai, V., Zloto, O., Maman, E. S., Cohen, K., Ellis, M., Lin, H.-Y., Hercbergs, A., et al. (2015) · Oncotarget · doi:10.18632/oncotarget.3566 · Cited by 36
“com/oncotarget onset and reduce aggressiveness of cancers [9, 12].”
BackgroundResultInfluentialEnvironmental Endocrinology: Parabens Hazardous Effects on Hypothalamic–Pituitary–Thyroid Axis
Azeredo, D. B. C., Anselmo, D. D. S., Soares, P., Graceli, J. B., Magliano, D. C., & Miranda‐Alves, L. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms242015246 · Cited by 40
Cho, Y. A., Kong, S., Shin, A., Lee, J., Lee, E. K., Lee, Y. J., & Kim, J. (2014) · BMC Cancer · doi:10.1186/1471-2407-14-873 · Cited by 37
“and proliferation or in stimulating angiogenesis [10].”
Loss of p53 activates thyroid hormone via type 2 deiodinase and enhances DNA damage
Nappi, A., Miro, C., Pezone, A., Tramontano, A., Cicco, E. D., Sagliocchi, S., Cicatiello, A. G., Murolo, M., Torabinejad, S., Abbotto, E., et al. (2023) · Nature Communications · doi:10.1038/s41467-023-36755-y · Cited by 37
Lee, Y.-S., Chin, Y., Yang, Y. S. H., Wei, P., Wu, H., Shih, A., Lu, Y.-T., Pedersen, J. Z., Incerpi, S., Liu, L. F., et al. (2016) · Steroids · doi:10.1016/j.steroids.2016.03.006 · Cited by 37
Chen, Y., Chen, Y.-S., Chin, Y., Li, Z., Shih, Y.-J., Yang, Y. S. H., Changou, C. A., Su, P.-Y., Wang, S.-H., Wu, Y.-H., et al. (2019) · Food and Chemical Toxicology · doi:10.1016/j.fct.2019.110693 · Cited by 33
Tetrac downregulates β-catenin and HMGA2 to promote the effect of resveratrol in colon cancer
Nana, A. W., Chin, Y., Lin, C., Ho, Y., Bennett, J. A., Shih, Y.-J., Chen, Y., Changou, C. A., Pedersen, J. Z., Incerpi, S., et al. (2017) · Endocrine Related Cancer · doi:10.1530/erc-17-0450 · Cited by 33
“2010, Moeller & Führer 2013).”
Deziel, N. C., Yi, H., Stapleton, H. M., Huang, H., Zhao, N., & Zhang, Y. (2018) · BMC Cancer · doi:10.1186/s12885-018-4553-9 · Cited by 36
“Epidemiologic evidence suggests that T3 and T4 exhibit tumor-promoting effects for other hormonally related cancers, such as ovarian, prostate, pancreatic cancers [52].”
BackgroundChoi, J., Lee, J., Yang, S. S., Lee, E. K., Hwangbo, Y., & Kim, J. (2018) · Scientific Reports · doi:10.1038/s41598-018-33338-6 · Cited by 36
Significance of nuclear cathepsin V in normal thyroid epithelial and carcinoma cells
Al-Hashimi, A., Venugopalan, V., Sereesongsaeng, N., Tedelind, S., Pinzaru, A. M., Hein, Z., Springer, S., Weber, E., Führer, D., Scott, C. J., et al. (2020) · Biochimica et Biophysica Acta (BBA) - Molecular Cell Research · doi:10.1016/j.bbamcr.2020.118846 · Cited by 34
Self-citationWeng, C., Okawa, E. R., Roberts, M. B., Park, S. K., Umbricht, C. B., Manson, J. E., & Eaton, C. B. (2020) · Thyroid · doi:10.1089/thy.2019.0426 · Cited by 36
“A hypothyroid state reduced the size and proliferation of malignant breast tumors and increased tumor necrosis in vitro, but the tumors exhibited a higher metastatic occurrence (17,37).”
BackgroundThyroid Hormone Promotes β-Catenin Activation and Cell Proliferation in Colorectal Cancer
Lee, Y.-S., Chin, Y.-T., Shih, Y.-J., Nana, A. W., Chen, Y.-R., Wu, H.-C., Yang, Y.-C. S. H., Lin, H.-Y., & Davis, P. J. (2018) · Hormones and Cancer · doi:10.1007/s12672-018-0324-y · Cited by 28
“Instead of classical genomic actions directed by the T3-bound thyroid hormone receptors (TRα and TRβ), the cancerpromoting effects of thyroid hormones are mostly related to their cell surface receptor integrin αvβ3 and the function of circulating T4 [2, 3].”
Backgroundde Groot, S., Janssen, L. G. M., Charehbili, A., Dijkgraaf, E. M., Smit, V. T. H. B. M., Kessels, L. W., van Bochove, A., van Laarhoven, H. W. M., Kranenbarg, E. M., van Leeuwen‐Stok, A. E., et al. (2015) · Breast Cancer Research and Treatment · doi:10.1007/s10549-014-3256-4 · Cited by 30
“Several epidemiological studies show a positive association between plasma thyroid hormones (TH)—triiodothyronine (T3) and the prohormone thyroxine (T4)—levels and breast cancer risk [1–3], which supports the notion that TH promote tumor growth [4].”
BackgroundHu, M., Zhang, C., Liang, L., Wang, S., Zheng, X., Zhang, Q., Jiang, C., Zhong, Q., & Huang, F. (2019) · Head & Neck · doi:10.1002/hed.25691 · Cited by 30
“The association between thyroid hormones and cancer has also been investigated.(29) However, in the large European Prospective Investigation into Cancer and Nutrition (EPIC) cohort study, the low TSH levels were found to be associated with thyroid cancer oncogenesis.”
BackgroundThe Drosophila ecdysone receptor promotes or suppresses proliferation according to ligand level
Perez‐Mockus, G., Cocconi, L., Alexandre, C., Aerne, B. L., Salbreux, G., & Vincent, J. (2023) · Developmental Cell · doi:10.1016/j.devcel.2023.08.032 · Cited by 31
“76,77 Moreover, our work highlights the possibility that inactivation of the receptor, e.g., with a chemical degrader, may not achieve the same objective as hormone depletion.”
Zhang, P., Chen, L., Song, Y., Li, X., Sun, Y., Xiao, Y., & Xing, Y. (2016) · Experimental Cell Research · doi:10.1016/j.yexcr.2016.08.019 · Cited by 32
Thyroid and androgen receptor signaling are antagonized by μ‐Crystallin in prostate cancer
Aksoy, O., Pěnčík, J., Hartenbach, M., Moazzami, A. A., Schlederer, M., Balber, T., Varady, A., Philippe, C., Baltzer, P., Mazumder, B., et al. (2020) · International Journal of Cancer · doi:10.1002/ijc.33332 · Cited by 28
“Intracellular thyroid hormone function in the prostate is dependent on CRYM expression levels.(10,11) Previous reports demonstrated that CRYM expression was downregulated in PCa patients who underwent ADT(12) and that expression of CRYM was also downregulated in a PCa xenograft tumor model.”
BackgroundThe antigenic link between thyroid autoimmunity and breast cancer
Muller, I., & Barrett-Lee, P. J. (2019) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2019.05.013 · Cited by 27
Thyroid hormone receptor beta: Relevance in human health and diseases
Rehman, G., Kumari, N., Bano, F., & Tyagi, R. K. (2023) · Endocrine and Metabolic Science · doi:10.1016/j.endmts.2023.100144 · Cited by 33
Sarosiek, K., Gandhi, A. V., Saxena, S., Kang, C. Y., Chipitsyna, G. I., Yeo, C. J., & Arafat, H. A. (2016) · Journal of Thyroid Research · doi:10.1155/2016/2454989 · Cited by 24
“Differences in gender, smoking status, venous-lymphatic invasion, perineural invasion, T stage, N stage, prognostic stage, and differentiation by hypothyroid status were determined by Chi-square test.”
MethodThyroid hormone induces cellular senescence in prostate cancer cells through induction of DEC1
Kotolloshi, R., Mirzakhani, K., Ahlburg, J., Kraft, F., Pungsrinont, T., & Baniahmad, A. (2020) · The Journal of Steroid Biochemistry and Molecular Biology · doi:10.1016/j.jsbmb.2020.105689 · Cited by 39
Duff, S., Connolly, C. M., & Buggy, D. J. (2016) · International Anesthesiology Clinics · doi:10.1097/aia.0000000000000120 · Cited by 28
“This introduces uncertainty into the results as increasing thyroid hormone levels appear to be correlated with cancer incidence and progression.(20) In a phase I/II study in glioblastoma, medically induced hypothyroidism was associated with an improved OS.”
BackgroundMuller, I., Kilburn, L., Taylor, P. N., Barrett-Lee, P. J., Bliss, J. M., Ellis, P., Ludgate, M., & Dayan, C. M. (2017) · European Thyroid Journal · doi:10.1159/000460246 · Cited by 25
Incidence of hypothyroidism after treatment for breast cancer—a Danish matched cohort study
Falstie‐Jensen, A. M., Öztürk, B., Kjærsgaard, A., Lorenzen, E. L., Jensen, J. D., Reinertsen, K. V., Dekkers, O. M., Ewertz, M., & Cronin-Fenton, D. P. (2020) · Breast Cancer Research · doi:10.1186/s13058-020-01337-z · Cited by 28
Costa, L. E. S., Clementino-Neto, J., Mendes, C. B., Franzon, N. H., Costa, E. D. O., Moura‐Neto, V., & Ximenes-da-Silva, A. (2019) · Frontiers in Neuroscience · doi:10.3389/fnins.2019.00317 · Cited by 21
“In this regard, some epidemiological studies have provided evidence of the role of thyroid hormones in promoting tumor cell proliferation, arguing that several different types of tumors exhibit increased growth in patients with a history of hyperthyroidism (Moeller and Führer, 2013).”
BackgroundBrenner, S., Klameth, L., Riha, J., Schölm, M., Hamilton, G., Bajna, E., Ausch, C., Reiner, A., Jäger, W. R., Thalhammer, T., et al. (2014) · Cancer Letters · doi:10.1016/j.canlet.2014.09.025 · Cited by 26
Falstie‐Jensen, A. M., Kjærsgaard, A., Lorenzen, E. L., Jensen, J. D., Reinertsen, K. V., Dekkers, O. M., Ewertz, M., & Cronin-Fenton, D. P. (2019) · Breast Cancer Research · doi:10.1186/s13058-019-1122-3 · Cited by 25
Popławski, P., Wiśniewski, J. R., Rijntjes, E., Richards, K. H., Rybicka, B., Köhrle, J., & Piekiełko‐Witkowska, A. (2017) · PLoS ONE · doi:10.1371/journal.pone.0190179 · Cited by 22
Physiological Role and Use of Thyroid Hormone Metabolites - Potential Utility in COVID-19 Patients
Fröhlich, E., & Wahl, R. (2021) · Frontiers in Endocrinology · doi:10.3389/fendo.2021.587518 · Cited by 20
Fröhlich, E., & Wahl, R. (2015) · European Journal of Endocrinology · doi:10.1530/eje-15-0713 · Cited by 23
Lee, J. H., Park, Y. W., & Lee, S. W. (2019) · The World Journal of Men s Health · doi:10.5534/wjmh.180084 · Cited by 19
“There are several pathways that may explain the relationship between cancer and thyroid function, as follow [17]: first, the binding of thyroid hormone to thyroid hormone receptors initiates the oncogenic phosphatidylinositol-3-kinase (PI3K) pathway [4,17], then the PI3K pathway induces the expression of transcription…”
BackgroundThe thyroid status reprograms T cell lymphoma growth and modulates immune cell frequencies
Sterle, H., Arcos, M. L. B., Valli, E., Paulazo, M. A., Méndez‐Huergo, S. P., Blidner, A. G., Cayrol, F., Flaqué, M. C. D., Klecha, A. J., Medina, V. A., et al. (2015) · Journal of Molecular Medicine · doi:10.1007/s00109-015-1363-2 · Cited by 20
“Reduced growth and prolonged host survival were described in hypothyroid with respect to control tumor-bearing animals [15].”
BackgroundResultHypothyroidism induces oxidative stress and DNA damage in breast
Peixoto, M. S., de Souza, A., Andrade, I. S., el Giusbi, C. D. C., de Faria, C. C., Hecht, F., Miranda‐Alves, L., Ferreira, A. C. F., de Carvalho, D. P., & Fortunato, R. S. (2021) · Endocrine Related Cancer · doi:10.1530/erc-21-0010 · Cited by 23
Understanding the Healthy Thyroid State in 2015
F�hrer, D., Brix, K., & Biebermann, H. (2015) · European Thyroid Journal · doi:10.1159/000431318 · Cited by 19
Self-citationThe effect of thyroid dysfunction on breast cancer risk: an updated meta-analysis
Tran, T., Kitahara, C. M., Leenhardt, L., de Vathaire, F., Boutron‐Ruault, M., & Journy, N. (2022) · Endocrine Related Cancer · doi:10.1530/erc-22-0155 · Cited by 24
Vargas‐Uricoechea, H. (2024) · World Journal of Oncology · doi:10.14740/wjon1728 · Cited by 18
“…in rodents and humans have found an increased risk of prostate, breast, colon, and lung cancer in the presence of elevated T4 and T3, and although the role of this elevation on the risk of TC is not well established, angiogenesis clearly plays a major role in its development and progression [30].”
BackgroundHe, L.-R., Qiao, W., Liao, Z. X., Komaki, R. U., Ho, L., Hofstetter, W. L., & Lin, S. H. (2015) · BMC Cancer · doi:10.1186/s12885-015-1095-2 · Cited by 18
“In animal models, thyroid hormone can stimulate tumor growth and metastasis, whereas hypothyroidism shows the opposite effects [17,18].”
BackgroundTriiodothyronine regulates cell growth and survival in renal cell cancer
Czarnecka, A. M., Matak, D., Szymański, Ł., Czarnecka, K. H., Lewicki, S., Zdanowski, R., Brzeziańska‐Lasota, E., & Szczylik, C. A. (2016) · International Journal of Oncology · doi:10.3892/ijo.2016.3668 · Cited by 25
Tetrac as an anti-angiogenic agent in cancer
Schmohl, K. A., Nelson, P. J., & Spitzweg, C. (2019) · Endocrine-Related Cancer · doi:10.1530/erc-19-0058 · Cited by 18
Wu, N.-X., Zhu, S., Liu, C., Yan, Y.-H., Wang, J., Hong, A.-B., Wang, L.-Q., Zeng, Q., Sun, J., Chen, D., et al. (2022) · Environmental Science and Pollution Research · doi:10.1007/s11356-022-20741-w · Cited by 18
“2012), as well as stimulate tumor growth and metastasis(Moeller and Führer 2013; Lin et al.”
BackgroundInfluentialUchuya-Castillo, J., Aznar, N., Frau, C., Martinez, P., Nevé, C. L., Marisa, L., Penalva, L. O. F., Laurent‐Puig, P., Puisieux, A., Scoazec, J., et al. (2018) · Oncotarget · doi:10.18632/oncotarget.25741 · Cited by 18
“For instance, an increased risk of colon, lung, prostate, and breast cancer with increased TH has been demonstrated in epidemiological studies, even suggesting a TH dosedependent effect on cancer occurrence [8].”
BackgroundGreenspan, B. S., Siegel, J. A., Hassan, A., & Silberstein, E. B. (2019) · Journal of Nuclear Medicine · doi:10.2967/jnumed.119.235929 · Cited by 17
“5 Gy (50 rad); (3) the estimated doses are too low to expect increased cancer incidence or mortality; (4) since the relative risks are likely inaccurate, comparing them with the assumed and not directly measured doses is meaningless, especially since there are other known causative factors that are much more important…”
BackgroundWallis, D. J., Truong, L., Du, J. K. L., Tanguay, R. L., & Reif, D. M. (2021) · Toxics · doi:10.3390/toxics9040077 · Cited by 16
Thyroid hormone signaling in the intestinal stem cells and their niche
Giolito, M. V., & Plateroti, M. (2022) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-022-04503-y · Cited by 18
Shao, W., Kühn, C., Mayr, D. C., Ditsch, N. C., Kailuweit, M., Wolf, V., Harbeck, N., Mahner, S., Jeschke, U., Cavaillès, V., et al. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21010330 · Cited by 23
Perrotta, C., Palma, C. D., Clementi, E., & Cervia, D. (2015) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2015.00236 · Cited by 15
“However, our current understanding of the effects of THs on cancer cells reflects a rather complex picture and conflicting results mainly obtained in in vitro and in vivo animal models have also been reported.”
BackgroundInfluentialThyroid Hormones as Renal Cell Cancer Regulators
Szymański, Ł., Matak, D., Bartnik, E., Szczylik, C. A., & Czarnecka, A. M. (2016) · Journal of Signal Transduction · doi:10.1155/2016/1362407 · Cited by 15
Fontana, C. M. L., Zyla, L., Santiano, F. E., Sasso, C. V., Cuello-Carrión, F. D., Creydt, V. P., Fanelli, M. A., & Carón, R. W. (2017) · Histochemistry and Cell Biology · doi:10.1007/s00418-017-1544-x · Cited by 14
“Other authors have observed that hypothyroid patients showed longer survival than euthyroid patients (Moeller and Fuhrer 2013).”
ResultWang, X., Liu, X., Li, Y., Tang, M., Meng, X., Chai, Y., Zhang, L., & Zhang, H. (2023) · BMC Pulmonary Medicine · doi:10.1186/s12890-023-02588-0 · Cited by 14
“Some studies suggested TH and TH receptors can promote cancers through mediating by phosphati-dylinositol-3-kinase and MAPK [38].”
BackgroundAutoimmune conditions and pancreatic cancer risk in older American adults
Yuan, F., Pfeiffer, R. M., Julián‐Serrano, S., Arjani, S., Barrett, M. J., Koshiol, J. E., & Stolzenberg‐Solomon, R. Z. (2022) · International Journal of Cancer · doi:10.1002/ijc.34235 · Cited by 15
“Immunosuppressive treatments for ulcerative colitis and localized scleroderma,(46,47) hyperglycemia and exogenous insulin treatment related to type 1 diabetes,(38) and tumorpromoting effect of thyroid hormones for Graves' disease could also contribute.(48) The associations of pure red cell aplasia and aplastic anemia…”
BackgroundBorlak, J. T., Länger, F. P., & Chatterji, B. (2018) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2018.06.019 · Cited by 12
Tetrac Delayed the Onset of Ocular Melanoma in an Orthotopic Mouse Model
Ashur‐Fabian, O., Zloto, O., Fabian, I., Tsarfaty, G., Ellis, M. H., Steinberg, D. M., Hercbergs, A. H., Davis, P. J., & Fabian, I. D. (2019) · Frontiers in Endocrinology · doi:10.3389/fendo.2018.00775 · Cited by 13
Mourouzis, I. S., Tzovaras, A. A., Armonis, B., Ardavanis, A. S., Skondra, M., Misitzis, J., Pectasides, D., & Pantos, C. I. (2015) · International Journal of Endocrinology · doi:10.1155/2015/765406 · Cited by 13
Puhr, H. C., Wolf, P. S., Berghoff, A. S., SCHOPPMANN, S. F., Preusser, M., & Ilhan‐Mutlu, A. (2019) · Hormones and Cancer · doi:10.1007/s12672-019-00374-1 · Cited by 13
“Also, loss of normal functions of thyroid receptors might also contribute to cancer development, progression, and metastasis [10, 11].”
BackgroundMalignant neoplasms in people with hypothyroidism in Spain: A population-based analysis
Díez, J. J., & Iglesias, P. (2022) · PLoS ONE · doi:10.1371/journal.pone.0275568 · Cited by 12
“Experimental studies have suggested a relationship between thyroid function and cancer development [5].”
BackgroundWang, X.-S., Wu, S., Peng, Z., & Zhu, H. (2021) · International Journal of General Medicine · doi:10.2147/ijgm.s339921 · Cited by 12
“of many substrates including thyroid hormones, which regulated the progression of cancer through binding the thyroid hormone receptor.(21) Importantly, thyroid hormone concentration is considered as an independent risk factor for the development and progression of thyroid cancer.”
BackgroundFan, X., You, W., Chen, Y., Nie, C., Wang, X., Lei, C., Song, J., & Luo, H.-L. (2024) · Heliyon · doi:10.1016/j.heliyon.2024.e24391 · Cited by 11
“Relevant studies have shown [15] that TSH not only promotes thyroid cancer, but also promotes breast cancer, pancreatic cancer, ovarian cancer and other malignant tumors.”
BackgroundCarmona-Cortés, J., Rodríguez‐Gómez, I., Wangensteen, R., Banegas, I., Garcia-Lora, A. M., Quesada, A., Osuna, A., & Vargas, F. (2014) · Tumor Biology · doi:10.1007/s13277-014-1726-2 · Cited by 14
Zhang, Q., Mu, Y., Jiang, X. M., Zhao, Y., Wang, Q., & Shen, Z. (2024) · Frontiers in Endocrinology · doi:10.3389/fendo.2024.1335149 · Cited by 13
“…cancer, but the available epidemiology suggests that reduced levels Scatter plots for this MR analyses of the causal relationship between thyroid dysfunction and gastric cancer: (A of thyrotropic hormone can lead to an increased risk of lung, breast, colon, prostate, and breast cancers (30, 31).”
BackgroundThyroid hormones and their membrane receptors as therapeutic targets for T cell lymphomas
Cremaschi, G., Cayrol, F., Sterle, H., Flaqué, M. C. D., & Arcos, M. L. B. (2016) · Pharmacological Research · doi:10.1016/j.phrs.2016.02.001 · Cited by 14
Lee, J., Lee, M.-K., Lee, J. H., Kim, K., Bae, K., & Sohn, S. Y. (2024) · Thyroid · doi:10.1089/thy.2024.0178 · Cited by 10
Nauman, P. (2015) · Endokrynologia Polska · doi:10.5603/ep.2015.0055 · Cited by 10
“Some recent review papers [15, 16] focusing on the participation of thyroid hormones and their recep-”
BackgroundLiu, Y., Qu, K., Hai, Y., Li, X., Zhao, L., & Zhao, C. (2017) · Journal of Cellular Biochemistry · doi:10.1002/jcb.26425 · Cited by 11
Targeting Androgen, Thyroid Hormone, and Vitamin A and D Receptors to Treat Prostate Cancer
Hantusch, B., Kenner, L., Stanulović, V. S., Hoogenkamp, M., & Brown, G. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25179245 · Cited by 12
“From in vitro studies, T3 supported the growth of lung, breast, ovarian, and squamous-cell cancer cells [72,96,125], and THs have a direct stimulatory effect on some key oncogenic signaling pathways, including the phosphatidylinositol-3-kinase (PI3K)- and extracellular signal-regulated kinase…”
BackgroundOvčariček, P. P., Fröbe, A., Verburg, F. A., Murgić, J., Butković, M. B., Ovčariček, S., Mažuran, B., Krušlin, B., Jakovčević, D., Šoipi, Š., et al. (2020) · Anticancer Research · doi:10.21873/anticanres.14199 · Cited by 11
Barr, C. E., Njoku, K., Hotchkies, L., Ryan, N. A. J., Wan, Y.-L. L., Davies, D. A., Razvi, S., & Crosbie, E. J. (2021) · Cancers · doi:10.3390/cancers13215444 · Cited by 10
Process to radioactive iodine treatment for Graves’ hyperthyroidism: condemned or absolved?
Bartalena, L., Gallo, D., Kahaly, G. J., Piantanida, E., & Tanda, M. L. (2025) · Journal of Endocrinological Investigation · doi:10.1007/s40618-025-02653-x · Cited by 8
Thyroid Hormone Effects on Mesenchymal Stem Cell Biology in the Tumour Microenvironment
Schmohl, K. A., Müller, A. M., Nelson, P. J., & Spitzweg, C. (2019) · Experimental and Clinical Endocrinology & Diabetes · doi:10.1055/a-1022-9874 · Cited by 12
FT3 to FT4 Conversion Ratio May Be an Independent Prognostic Factor in Pancreatic Cancer Patients
Majos, A., Sewerynek, E., Grząsiak, O., Ciesielski, W., Hogendorf, P., Hołyński, J., Strzelczyk, J., & Durczyński, A. (2022) · Biomedicines · doi:10.3390/biomedicines11010077 · Cited by 10
Breast cancer cells utilize T3 to trigger proliferation through cellular Ca2+ modulation
Tawfik, I., Schlick, K., Ostaku, J., Bresilla, D., Gabrijelčič, S., Gottschalk, B., Sokolowski, A., Malle, E., Kalinová, K., Hirtl, M., et al. (2024) · Cell Communication and Signaling · doi:10.1186/s12964-024-01917-y · Cited by 9
“In epidemiological studies, low TSH level were associated with an increased risk for colon, lung, prostate, and breast cancer, while high TH levels were further associated with advanced clinical stages of breast cancer [5, 6].”
BackgroundResultThyroid dysfunction and breast cancer risk — an unfinished story
Chaker, L., & Visser, T. J. (2016) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2016.48 · Cited by 10
Popławski, P., Piekiełko‐Witkowska, A., & Nauman, A. (2015) · Endokrynologia Polska · doi:10.5603/ep.a2017.0052 · Cited by 8
Metadata
- Authors
- Moeller, L. C., & Führer, D.
- Affiliations
- University of Duisburg-Essen (DE)
- ORCID
- Moeller, Lars C
- Venue
- Endocrine-Related Cancer
- Publisher
- Bioscientifica
- Published
- 2013-04-01
- Volume
- 20
- Issue
- 2
- Pages
- R19-R29
- ISSN
- 1351-0088 (ISSN-L)
- 1479-6821
- OpenAlex
- W2128280017
- Cited by
- 184
- References
- 76
- Citations by year
- 2026: 7 · 2025: 14 · 2024: 16 · 2023: 14 · 2022: 18 · 2021: 18 · 2020: 15 · 2019: 19 · 2018: 13 · 2017: 10 · 2016: 14 · 2015: 18 · 2014: 8
- FWCI
- 1.95
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Endocrine Related Cancer (publishedVersion)
- PubMed (publishedVersion)
- Universitätsbibliographie, Universität Duisburg-Essen (submittedVersion)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Thyroid Disorders and Treatments
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Thyroid Cancer Diagnosis and Treatment
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Growth Hormone and Insulin-like Growth Factors
- Keywords
- thyroid hormones, thyroid hormone receptor, cancer, hypothyroidism, tumor promotion, phosphatidylinositol 3-kinase, MAPK signaling, angiogenesis, alpha v beta 3 integrin, thyroid-stimulating hormone, colon cancer, lung cancer, prostate cancer, breast cancer, glioblastoma, head and neck cancer, renal cell carcinoma, sunitinib, tyrosine kinase inhibitors, cancer survival, metastasis
- MeSH terms
- Animals, Disease Models, Animal, Humans, Neoplasms, Receptors, Thyroid Hormone, Thyroid Hormones
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.